Patents by Inventor Beom Seon SUH

Beom Seon SUH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF
    Publication number: 20250082762
    Abstract: The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.
    Type: Application
    Filed: November 15, 2024
    Publication date: March 13, 2025
    Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, UBIX THERAPEUTICS, INC.
    Inventors: Pil Ho KIM, Sung Yun CHO, Jae Du HA, Chi Hoon PARK, Jong Yeon HWANG, Hyun Jin KIM, Song Hee LEE, Ye Seul LIM, Han Wool KIM, Sun Mi YOO, Beom Seon SUH, Ji Youn PARK, Je Ho RYU, Jung Min AHN, Hee Jung MOON, Ho Hyun LEE
  • BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF
    Publication number: 20250073341
    Abstract: The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.
    Type: Application
    Filed: November 15, 2024
    Publication date: March 6, 2025
    Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, UBIX THERAPEUTICS, INC.
    Inventors: Pil Ho KIM, Sung Yun CHO, Jae Du HA, Chi Hoon PARK, Jong Yeon HWANG, Hyun Jin KIM, Song Hee LEE, Ye Seul LIM, Han Wool KIM, Sun Mi YOO, Beom Seon SUH, Ji Youn PARK, Je Ho RYU, Jung Min AHN, Hee Jung MOON, Ho Hyun LEE
  • Bifunctional heterocyclic compound having BTK degradation function via ubiquitin proteasome pathway, and use thereof
    Patent number: 12161722
    Abstract: The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.
    Type: Grant
    Filed: June 24, 2022
    Date of Patent: December 10, 2024
    Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, UBIX THERAPEUTICS, INC.
    Inventors: Pil Ho Kim, Sung Yun Cho, Jae Du Ha, Chi Hoon Park, Jong Yeon Hwang, Hyun Jin Kim, Song Hee Lee, Ye Seul Lim, Han Wool Kim, Sun Mi Yoo, Beom Seon Suh, Ji Youn Park, Je Ho Ryu, Jung Min Ahn, Hee Jung Moon, Ho Hyun Lee
  • NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF
    Publication number: 20240285778
    Abstract: The present invention relates to a novel heterocyclic compound and a composition, for preventing or treating a cancer, an autoimmune disease, and an inflammatory disease, comprising same. The novel heterocyclic compound of the present invention is a bifunctional compound having a Bruton's tyrosine kinase (BTK) degradation function via a ubiquitin proteasome pathway, and may be utilized as a composition for preventing or treating a cancer, an autoimmune disease, and Parkinson's disease.
    Type: Application
    Filed: June 24, 2022
    Publication date: August 29, 2024
    Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, UBIX THERAPEUTICS, INC.
    Inventors: Pil Ho KIM, Sung Yun CHO, Jae Du HA, Chi Hoon PARK, Jong Yeon HWANG, Hyun Jin KIM, Song Hee LEE, Ye Seul LIM, Han Wool KIM, Sun Mi YOO, Beom Seon SUH, Ji Youn PARK, Je Ho RYU, Jung Min AHN, Hee Jung MOON, Ho Hyun LEE